DHEA

Dehydroepiandrosterone is a C19 steroid that ranks among the most plentiful steroids in human circulation. Most of it travels in the bloodstream as its sulfated ester, DHEA-S, which is present at far higher concentrations than free DHEA and acts as a slowly released reservoir that prolongs the compound's biological presence ^[1]. The two forms interconvert, and clinicians often measure DHEA-S as a marker of adrenal androgen output.

The hormone is synthesized mainly in the zona reticularis of the adrenal cortex, with additional production in the gonads and in the brain ^[1]. Rather than acting strongly on its own, DHEA functions largely as an intracrine precursor: peripheral tissues take it up and use their own enzymes to convert it into active androgens and estrogens that then work locally, an arrangement that lets different tissues tune their own hormone exposure ^[1][2]. Circulating levels rise through puberty, peak around the third decade of life, and then decline gradually, reaching low, prepubertal-like values in advanced age; this age-related fall is what first drew attention to DHEA as a possible anti-aging agent ^[1][3].

Because of that decline, DHEA has been marketed as a supplement aimed at improving wellbeing, libido, mood, and body composition, although reviews of controlled trials in otherwise healthy postmenopausal women describe inconsistent results and limited safety data ^[3]. The strongest signal for benefit appears in people with adrenal insufficiency, whose own production is impaired ^[3]. DHEA has also been studied in reproductive medicine as an androgen precursor that may support ovarian follicle development in women with diminished ovarian reserve ^[4], and it has been examined for effects on bone, immune function, endothelial function, and insulin sensitivity, though its overall clinical value remains unsettled ^[1].

In the United States, DHEA is sold over the counter as a dietary supplement, while a purified form, prasterone, is available by prescription, including an intravaginal preparation used for painful intercourse associated with vaginal atrophy. Regulatory treatment differs by country, with some jurisdictions classifying it as a prescription or controlled substance, and the World Anti-Doping Agency prohibits it in competitive sport because of its conversion to testosterone. It is supplied as oral capsules and tablets, as intravaginal inserts, and in topical formulations.

DHEA is generally well tolerated at supplemental doses, but because it is a direct precursor to potent androgens and estrogens its adverse effects are largely hormonal. Reported side effects include acne, oily skin, facial hair growth and scalp hair thinning, and, in women, mild virilizing effects; in men, elevated estradiol and, theoretically, effects on prostate tissue are of concern.

It may lower HDL cholesterol in women and can, in principle, promote hormone-sensitive cancers, so it is contraindicated in people with a history of breast, ovarian, uterine, or prostate cancer. DHEA can also disturb sleep, provoke irritability or, uncommonly, mania in susceptible individuals, and it may interact with antidepressants, hormone therapies, and drugs metabolized by the liver. Long-term safety data are limited, and the quality of over-the-counter products varies widely; it is banned in competitive sport by the World Anti-Doping Agency.

DHEA was first isolated in 1934 by the German biochemist Adolf Butenandt and his colleague Kurt Tscherning, who crystallized it from male urine; the compound was long regarded as an inert adrenal by-product. Interest shifted to the brain in 1981, when Corpechot, Robel, Baulieu and colleagues demonstrated that DHEAS is present in rat brain at concentrations far exceeding plasma and persists after removal of the adrenals and gonads, proving local synthesis; on this basis Etienne-Emile Baulieu coined the term neurosteroid.

Passage of the Dietary Supplement Health and Education Act in 1994 left DHEA available over the counter in the United States even as related anabolic steroids were restricted, fueling its popularity as an anti-aging supplement. Large trials followed, including the French DHEAge study in 2000 and the DHEA depression trials of Wolkowitz and Schmidt, which established modest antidepressant signals while tempering broader anti-aging claims.

DHEA occupies an unusual position between endocrinology and the supplement market. Within neuropharmacology it is respected as a foundational neurosteroid whose study helped define the field, and it carries reasonably credible evidence for antidepressant and pro-cognitive effects, particularly in midlife depression, adrenal insufficiency, and stress resilience. In the wider wellness culture it is often marketed with exaggerated anti-aging, libido, and body-composition claims that clinical trials only partially support. Serious commentators treat it as a genuine hormone rather than a benign vitamin, cautioning that its precursor status makes self-dosing less trivial than typical nootropics; it remains one of the most widely used yet most debated over-the-counter neuroactive steroids.